Biomarkers and Microarrays
A biomarker, or regular marker, is a quantifiable pointer of some organic state or condition. A biomarker is a test that can be used to help break down a condition or to help screen a condition or response to treatment. They are used as a piece of various scopes of prescription both in standard restorative practice and besides in research, especially in clinical preliminaries. In medication, a biomarker can be a detectable substance that is brought into an actual existence structure as an approach to examine organ work or various pieces of prosperity. For example, rubidium chloride is used as a radioactive isotope to evaluate perfusion of heart muscle.
Biomarkers continue winding up continuously noteworthy in research and social protection applications, as affirm by the overall market for things required in their ID, endorsement, and use foreseen to accomplish USD 53.34 Billion by 2021 from USD 27.95 Billion of every 2016, creating at a CAGR of 13.8% in the midst of the guess time period (2016–2021).
Miniaturized scale cluster is an apparatus utilized in research center to identify the declarations of thousands of qualities in the meantime. Miniaturized scale cluster innovation has broad application in Pharmacogenomics. Similar investigation of the qualities from an unhealthy and an ordinary cell will recognize the biochemical constitution of the proteins which are combined by the infected qualities. The scientists can utilize this data for incorporating drugs that battle with these proteins and decrease their impact.
DNA small scale cluster innovation helps in the distinguishing proof of new qualities, to become familiar with the ailments like heart ailments, psychological instability, irresistible infection and particularly the investigation of malignant growth.
Related Conference of Biomarkers and Microarrays
20th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
18th International Conference on Human Genomics and Genomic Medicine
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Biomarkers and Microarrays Conference Speakers
Recommended Sessions
- Animal Genetics
- Bioinformatics and Computational Biology
- Biomarkers and Microarrays
- Cancer Genomics
- Clinical genomics
- Comparative Genomics
- Epigenomics and Epigenetics
- Functional Genomics
- Gene Editing and Genetic Engineering
- Genetic Disorder
- Genomic Instability
- Genomic Medicine
- Microbial Genomics
- Next generation sequencing
- Nutrigenomics
- Personalized and Regenerative Medicine
- Pharmacogenomics
- Plant Genomics and Molecular Pharming
- Structural Genomics
- Trends in Genomics and Pharmacogenomics
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2025 (Italy)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (France)
- Bioinformatics - HUMAN GENOME 2025 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (France)
- Cancer and stem cells - CRISPR 2025 (Italy)
- Cancer Genomics - HUMAN GENOME 2025 (France)
- Cancer Stem Cells and Oncology - Stemgen 2026 (France)
- Cardiovascular Regeneration - Stemgen 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (France)
- Cognitive Computing - HUMAN GENOME 2025 (France)
- Computational Biology - HUMAN GENOME 2025 (France)
- CRISPR technologies and society - CRISPR 2025 (Italy)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2025 (Italy)
- Drug Detection & Development in Bioinformatics - HUMAN GENOME 2025 (France)
- Emergency Medicine - HUMAN GENOME 2025 (France)
- Epigenetics Biomarkers - HUMAN GENOME 2025 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (France)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (France)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (France)
- Genetically Modified Organisms - HUMAN GENOME 2025 (France)
- Genome editing and gene regulation in human health - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2025 (Italy)
- Genome Editing Methods and Novel Tools - CRISPR 2025 (Italy)
- Genome Mapping - HUMAN GENOME 2025 (France)
- Genomic Approach to Drug Discovery - HUMAN GENOME 2025 (France)
- Genomic Information in Medicine - HUMAN GENOME 2025 (France)
- Genomic Vaccination - HUMAN GENOME 2025 (France)
- Genomics - HUMAN GENOME 2025 (France)
- Horizons of CRISPR biology - CRISPR 2025 (Italy)
- Human Gene Therapy - HUMAN GENOME 2025 (France)
- Human Genetics - HUMAN GENOME 2025 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (France)
- Infectious Diseases - HUMAN GENOME 2025 (France)
- Medicine Genomics - HUMAN GENOME 2025 (France)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (France)
- Personalized Medicine - HUMAN GENOME 2025 (France)
- Pharma Genomics & Pharma Informatics - HUMAN GENOME 2025 (France)
- Plant and Animal Biotechnology - CRISPR 2025 (Italy)
- Preimplantation Genetic Diagnosis - HUMAN GENOME 2025 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (France)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (France)
- Structural Biology and Bioinformatics - CRISPR 2025 (Italy)
- Therapeutic Genome Editing - CRISPR 2025 (Italy)